Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 5,758 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lymphoma Clear all
Terminated Phase 3 Interventional Results available

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

NCT00500240
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Insulin Glargine, Insulin Aspart
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

NCT01744691
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • Greenbrae, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

NCT00691652
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

NCT01991938
View directory record Official record
Conditions
Non Hematologic Cancers, Metastatic Cancer, Lymphoma
Interventions
VS-5584
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Results available

Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

NCT04524455
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, AMG 404, Dexamethasone Premedication
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool

NCT05386355
View directory record Official record
Conditions
COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
Interventions
COVID-19 Vaccine Uptake App, General Health App
Behavioral · Other
Lead sponsor
IDeA States Pediatric Clinical Trials Network
Network
Eligibility
18 Years and older
Enrollment
1,934 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Honolulu, Hawaii + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

NCT03939026
View directory record Official record
Conditions
Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma
Interventions
ALLO-501, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Gilbert, Arizona • Stanford, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

NCT07402876
View directory record Official record
Conditions
Primary Vitreoretinal Lymphoma
Interventions
ICM ADX-2191 injection, Monthly ADX-2191 injection
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

NCT00361140
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Myeloma, Lymphoma
Interventions
Busulfan, Fludarabine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 30, 2026, 4:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Persistent Postpartum Cardiovascular Dysfunction in Patients With Preeclampsia

NCT04063397
View directory record Official record
Conditions
Preeclampsia Severe or Mild, Cardiac Complication
Interventions
Echocardiogram, Blood draw
Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 30, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

NEO100 and High-Grade Meningioma

NCT05023018
View directory record Official record
Conditions
Residual, Progressive or Recurrent Grade II or III Meningioma
Interventions
NEO100
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

NCT00714259
View directory record Official record
Conditions
Multiple Myeloma, CLL / SLL, Non Hodgkin's Lymphoma, Waldenstroms, Mantle Cell Lymphoma
Interventions
Fludarabine, Total Body Irradiation, Infusion of Stem Cells
Drug · Radiation · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

NCT02309580
View directory record Official record
Conditions
T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma
Interventions
Ibrutinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

NCT01333046
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Antigen-Escalation Stage, Dose-Escalation Stage, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia

NCT00002588
View directory record Official record
Conditions
Leukemia
Interventions
etoposide, topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

NCT03739554
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia
Interventions
CYC065, Venetoclax
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated Phase 2 Interventional

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

NCT03207256
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
TGR-1202, TGR-1202 + Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

NCT01908777
View directory record Official record
Conditions
T Cell Non-Hodgkin Lymphoma
Interventions
High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
10
States / cities
Tampa, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated No phase listed Observational

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

NCT00813501
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Neuroblastoma, Therapy-related Toxicity
Interventions
immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 30, 2026, 4:45 PM EDT
Active, not recruiting Not applicable Interventional

Edwards EVOQUE Eos MISCEND Study

NCT02718001
View directory record Official record
Conditions
Mitral Valve Regurgitation (Degenerative or Functional)
Interventions
Edwards EVOQUE Eos Mitral Valve Replacement System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2033
U.S. locations
16
States / cities
Burlingame, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

NCT00077467
View directory record Official record
Conditions
Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
bortezomib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 30, 2026, 4:45 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

NCT06733441
View directory record Official record
Conditions
Lymphoma
Interventions
TLN-254
Drug
Lead sponsor
Treeline Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Stanford, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

NCT00439556
View directory record Official record
Conditions
CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bortezomib, Carmustine, Cytarabine, Etoposide, Filgrastim, Melphalan, Methotrexate, Rituximab, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 30, 2026, 4:45 PM EDT
Not listed Phase 2 Interventional

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

NCT00026429
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
denileukin diftitox
Biological
Lead sponsor
Pharmatech Oncology
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
6
States / cities
Pomona, California • Rancho Mirage, California • Saint Charles, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 30, 2026, 4:45 PM EDT